We are live on
!
Find out more
FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$3.89B
1-Year Est. Return
201.1%
This Fund
S&P 500
This Quarter
Est. Return
+35.19%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.72B
AUM Growth
+$386M
(+12%)
Cap. Flow
-$472M
Cap. Flow
% of AUM
-12.68%
Top 10 Holdings %
Top 10 Hldgs %
71.01%
Holding
52
New
5
Increased
6
Reduced
8
Closed
12
Top Buys
| 1 |
Vor Biopharma
VOR
|
+$47.4M |
| 2 |
RAPT
RAPT Therapeutics
RAPT
|
+$30.5M |
| 3 |
MannKind Corp
MNKD
|
+$23.3M |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$23.1M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$16.3M |
Top Sells
| 1 |
VRNA
Verona Pharma
VRNA
|
+$361M |
| 2 |
Krystal Biotech
KRYS
|
+$42.1M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
+$32.8M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$29.6M |
| 5 |
BridgeBio Pharma
BBIO
|
+$19.7M |
Sector Composition
| 1 | Healthcare | 99.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NewAmsterdam Pharma
NAMS
$3.63B
| $594M | 15.96% |
16,943,774
+241,818
| +1% | +$8.8M |
|
2
Mirum Pharmaceuticals
MIRM
$7.16B
| $537M | 14.42% |
6,795,121
| – | – |
|
3
Arcutis Biotherapeutics
ARQT
$3.47B
| $287M | 7.7% |
9,874,511
| – | – |
|
|
4
BridgeBio Pharma
BBIO
$15.7B
| $271M | 7.28% |
3,545,557
-299,900
| -8% | -$19.7M |
|
|
MBX
5
MBX Biosciences
MBX
$2.78B
| $210M | 5.64% |
6,652,013
| – | – |
|
6
Phathom Pharmaceuticals
PHAT
$875M
| $207M | 5.55% |
12,466,489
| – | – |
|
|
MAZE
7
Maze Therapeutics
MAZE
$1.5B
| $189M | 5.08% |
4,567,274
| – | – |
|
8
Trevi Therapeutics
TRVI
$2.46B
| $128M | 3.45% |
10,259,409
| – | – |
|
|
9
Krystal Biotech
KRYS
$10.1B
| $120M | 3.23% |
488,460
-200,000
| -29% | -$42.1M |
|
10
Disc Medicine
IRON
$2.81B
| $100M | 2.69% |
1,260,000
-178,534
| -12% | -$15.1M |
|
11
Erasca
ERAS
$5.91B
| $84.6M | 2.27% |
22,729,436
| – | – |
|
|
KALV
12
DELISTED
KalVista Pharmaceuticals
KALV
| $81.4M | 2.19% |
5,039,867
| – | – |
|
|
PVLA
13
Palvella Therapeutics
PVLA
$2.12B
| $75.6M | 2.03% |
722,400
| – | – |
|
|
RNAM
14
DELISTED
Avidity Biosciences
RNAM
| $70.9M | 1.9% |
983,125
+358,125
| +57% | +$23.1M |
|
15
Revolution Medicines
RVMD
$38.1B
| $63.5M | 1.71% |
797,455
-200,000
| -20% | -$13.1M |
|
16
Dyne Therapeutics
DYN
$3.76B
| $61.7M | 1.66% |
3,153,082
+434,977
| +16% | +$8.24M |
|
|
17
Tarsus Pharmaceuticals
TARS
$2.52B
| $59.7M | 1.6% |
728,644
-438,883
| -38% | -$32.8M |
|
18
Savara
SVRA
$1.13B
| $59.5M | 1.6% |
9,862,301
-1,600,000
| -14% | -$7.84M |
|
19
Cytokinetics
CYTK
$10.9B
| $59.4M | 1.6% |
934,642
+44,197
| +5% | +$2.75M |
|
|
ABVX
20
Abivax
ABVX
$12B
| $51M | 1.37% |
378,300
| – | – |
|
21
Lexeo Therapeutics
LXEO
$358M
| $43.9M | 1.18% |
4,424,725
| – | – |
|
22
Agios Pharmaceuticals
AGIO
$2.3B
| $34.8M | 0.94% |
1,279,754
| – | – |
|
|
23
Acadia Pharmaceuticals
ACAD
$4.39B
| $34.6M | 0.93% |
1,297,198
+683,361
| +111% | +$16.3M |
|
24
Zai Lab
ZLAB
$2.34B
| $33.6M | 0.9% |
1,902,320
+275,000
| +17% | +$6.44M |
|
|
RAPT
25
DELISTED
RAPT Therapeutics
RAPT
| $33.3M | 0.89% |
+983,333
| New | +$30.5M |
|
Similar funds
GAMH
MSI
CCM
TFM
SCM
MIM
AA
DACG